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ABSTRACT
Alternative processing of pre-mRNA transcripts is a
major source of protein diversity in eukaryotes and
has been implicated in several disease processes
including cancer. In this study we have performed
a genome wide analysis of alternative splicing
events in lung adenocarcinoma. We found that
2369 of the 17800 core Refseq genes appear to
have alternative transcripts that are differentially
expressed in lung adenocarcinoma versus normal.
According to their known functions the largest
subset of these genes (30.8%) is believed to be
cancer related. Detailed analysis was performed
for several genes using PCR, quantitative RT-PCR
and DNA sequencing. We found overexpression of
ERG variant 2 but not variant 1 in lung tumors
and overexpression of CEACAM1 variant 1 but not
variant 2 in lung tumors but not in breast or colon
tumors. We also identified a novel, overexpressed
variant of CDH3 and verified the existence and over-
expression of a novel variant of P16 transcribed
from the CDKN2A locus. These findings demon-
strate how analysis of alternative pre-mRNA proces-
sing can shed additional light on differences
between tumors and normal tissues as well as
between different tumor types. Such studies may
lead to the development of additional tools for
tumor diagnosis, prognosis and therapy.
INTRODUCTION
Non-small cell lung cancer (NSCLC) is the most common
cause of cancer-related death in the USA (1). While early
detection may improve outcomes, overall 5-year survival
rates for NSCLC are currently only 16% (2). New mole-
cular diagnostic tests and novel therapeutic strategies are
needed for this terrible disease. NSCLC is one of the most
studied tumor types in the scientiﬁc literature demon-
strated by the number of excellent studies on global gene
expression (3–6) and genome-wide DNA copy number
changes (7,8) that have been conducted in NSCLC.
These studies have enhanced our knowledge of lung
cancer biology, led to proposals for multicenter trials of
primary tumor gene expression for prognosis and treat-
ment and may identify avenues for novel therapeutic
development. A promising area that remains relatively
unexplored, however, is alternative splicing (AS) of
mRNA to produce functionally diﬀerent proteins. Such
studies may lead to improved diagnostic and prognostic
tools and may identify additional therapeutic targets for
NSCLC.
Alternative splicing of pre-mRNA is an important pro-
cess in normal metazoan development (9,10). Further-
more, recent bioinformatics analysis suggests that 65%
of human genes are alternatively spliced (11–14); a large
increase over prior estimates as low as 5% (15). AS is not
only involved in normal development, but is also asso-
ciated with human diseases including cancer (16–27).
For some genes, alternative transcripts are diﬀerentially
expressed between tumor and normal tissue and in a few
cases, the expression of AS variants has been associated
with tumor progression (28–32). However, most studies of
AS in human disease have used a targeted approach and
focused on individual genes. There is a great deal of poten-
tial for novel discovery from genome-wide studies of alter-
native splicing. Until recently such large scale studies have
been a considerable technical and bioinformatic challenge
but the introduction of new technology and powerful
data analysis software now makes them more feasible.
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1.0 ST Array from Aﬀymetrix to explore genome-wide
AS events in the most predominant histologic type of
NSCLC, lung adenocarcinoma. The study was designed
to identify cancer-associated alternative splicing events,
verify splice variants and to validate diﬀerential expression
of selected splice variants in independent tissue sets. Our
results demonstrate that a large number of known genes,
including well known oncogenes and tumor suppressors,
are alternatively spliced and diﬀerentially expressed
between normal lung and lung adenocarcinoma. These
ﬁndings may provide a new resource for diagnosis and
treatment of NSCLC.
MATERIALS AND METHODS
Specimens and RNA isolation
Snap frozen lung tissue specimens were obtained from
tissue banks at the Heart, Lung and Esophageal Surgery
Institute, University of Pittsburgh Medical Center.
This study involving human tissue was approved by the
Institutional Review Boards from both the University of
Pittsburgh and Mount Sinai School of Medicine. In total,
36 pairs of lung adenocarcinoma and adjacent normal
lung tissue plus 43 additional adenocarcinoma and squa-
mous cell carcinoma specimens were analyzed (see clinical
information for all patients in Supplementary Table S1).
All tumor specimens were determined to comprise >70%
tumor and adjacent normal specimens contained no
histologically evident tumor or contaminating tissues.
Forty, 5-micron sections from each tissue block were
cut and placed immediately in Qiagen RNA lysis buﬀer.
RNA was isolated using Qiagen kits with on-column
DNAse treatment to remove genomic DNA followed by
precipitation. Puriﬁed RNA was then quantiﬁed using
a NanoDrop spectrophotometer and RNA integrity was
determined by running aliquots on an Agilent Bioana-
lyzer. RNA integrity numbers were >6 in all cases.
RNA labeling, hybridization, data processing and quality
assessment
A total of 2mg of RNA from each of 20 tumor/normal
paired specimens (n¼40) was labeled with reagents
from Aﬀymetrix according to the manufacturers instruc-
tions. Hybridization cocktails containing 5–5.5mg of frag-
mented, end-labeled single-stranded cDNA were prepared
and hybridized to GeneChip Human Exon 1.0 ST arrays.
These arrays survey both gene expression and alternative
splicing patterns on a whole-genome scale on a single
array. The array contains  5.4 million, 5-mm features
(probes) grouped into 1.4 million probesets, interrogating
over 1 million exon clusters (33). Processed arrays were
scanned using the GeneChip Scanner 3000 7G. Aﬀymetrix
Expression Console Software
TM (version 1.0) was used to
perform quality assessment.
Data analysis
All exon array data was analyzed using tools in Partek
Genomic Suite 6.4 software (Partek Inc., St. Louis, MO).
The Robust Multi-array Analysis (RMA) (34) algorithm
was used for probeset (exon-level) intensity analysis.
Exon-level data was then ﬁltered to include only those
probesets that are in the ‘core’ meta-probe list, which
represents 17800 RefSeq genes and full-length GenBank
mRNAs. Within this gene set, the Analysis of Variance
(ANOVA) and multi test correction for P-values in
Partek Genomic Suite were used to identify alternative
splicing events. Tissue type (tumor versus normal in this
case) was chosen as the candidate variable in the ANOVA
model to obtain tumor-related splicing events. ANOVA
P-values were corrected using Bonferroni method. A list
of genes with signiﬁcant alternative spliced events was
generated by using a 0.05 FDR criterion as a signiﬁcant
cutoﬀ. Then the genes were sorted based on gene function
using Ingenuity Pathway Analysis software (Ingenuity
Systems, www.ingenuity.com). Subsequent veriﬁcation
and validation of splicing events was restricted to those
genes with functions identiﬁed as being associated with
cancer such as invasion, cell movement, apoptosis, cell
death, tumorigenesis, and diﬀerentiation, etc. The ﬂow
chart for data analyses was as follows:
(0) QC with Aﬀymetrix expression console.
(1) Probe-level analysis with GC-RMA in Partek GS.
(2) Alternative splice analysis of exon data with
ANOVA in Partek GS.
(3) Function analysis of genes with alternative splicing
in Ingenuity Pathway Analysis and generation of
a cancer-related gene list.
(4) Manual review of Partek gene view plots to identify
alternate splicing forms and determine the frequency
of changes observed in the patient set.
(5) Detailed manual analysis focusing on genes with
simple forms of alt splicing and high frequency of
changes. Reviewed Aﬀymetrix probeset sequences,
RefSeq database, Blatted probe sequences in UCSC
Genomic Browser.
(6) Identiﬁcation of genes with alternative splicing at
high frequency in this patient set (>50% patients
with same change).
(7) Veriﬁcation and validation.
Exon arraydata verification, splice event validation,
and varianttranscript quantification
Reverse transcription of 2mg RNA was performed in
100ml reaction volumes with random hexamer priming
and MMLV reverse transcriptase (Epicentre, Madison,
WI) (35). Diluted cDNA was used in all following PCR
or qPCR reactions. Standard PCR was carried out for
35 cycles using Titanium
TM Taq DNA Polymerase
(ClonTech, Mountain View, CA) starting with 25ng of
cDNA as template in a 50ml reaction. PCR products
were separated on 10% Criterion
TM Precast TBE Gels
(Bio-Rad, Hercules, CA) for visualization or 1% agarose
gels for DNA extractions using the MinElute
TM
Gel Extraction Kit (Qiagen, Inc., Valencia, CA).
Quantitative real-time PCR was performed using the
Brilliant SYBR Green QPCR kit (Stratagene, La Jolla,
CA) with 10ng of cDNA as template in a 5ml reaction
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Biosystems, Foster City, CA). PCR was run in triplicate
for each sample. Relative expression was calculated using
the delta-CT methods previously described (36) and with
B2M as the endogenous control gene. B2M was chosen
as it showed very little variability in the exon array data
among all samples. Bidirectional DNA sequencing
of novel transcripts was performed by the DNA Core
Facility at the Mount Sinai School of Medicine using
forward and reverse PCR primers.
Detailed methods for analysis of alternative splicing and
primer design for PCR are included in the Supplementary
Methods.
RESULTS
Data quality assessment identiﬁed no outlier arrays using
Expression Console Software. Spearman Rank correlation
of the hybridization control signal values between any two
chips was high (r
2 0.92). Thus, data from all arrays was
included in the alternative splicing ANOVA (Alt-splice
ANOVA). Analyzing the 17800 genes represented in
‘Core’ Probeset list, we identiﬁed a total of 2369 genes
that appear to have diﬀerential expression of alternate
transcripts between normal and tumor tissue (FDR
correction to establish a cutoﬀ P-value of 3.94e-6, corre-
sponding to the 0.05 FDR level). Gene function analysis
indicated that the largest subset (729/2369, 30.8%) of
these genes were cancer related (a full list of genes is
included in Supplementary Table S2) followed by other
functional categories such as tissue development, cellular
growth and proliferation, tissue morphology, and immune
response. Of the 729 cancer-related genes, 47 showed the
same alternate splicing event in 50% or more ( 10 of 20)
of patients. In addition, one gene (CDH3) showed alter-
native splicing in only 8 (40%) patients, but all of these
were female (8 of 14; 57%) indicating the possibility of
gender-speciﬁc, cancer related alternative splicing. Of the
48 genes, 20 have reported alternate splice variants in
the Entrez Gene database and the remaining 28 genes
have only one known transcript. The 48 genes can also
be further divided into categories as follows and listed in
Table 1: (i) six genes with known splice variants where
relevance of splice variants has been identiﬁed in cancer.
These include ADAM12, CEACAM1, and FGFR4
which have been associated speciﬁcally with lung cancer;
(ii) 14 genes with known splice variants but where
relevance of the splice variants to cancer has not been
determined; (iii) 28 potentially novel splice variants diﬀer-
entially expressed between normal lung and lung
adenocarcinoma.
Verification ofexon arraydata
The ﬁrst step in veriﬁcation of alternative splicing was to
verify the exon array expression data for regions of genes
(exons) that appeared to have diﬀerential expression in
tumor and normal samples. Eleven genes (ARMET,
CDKN1A, CDKN2A, CDKN2B, CEACAM1, ERG,
FOXP1, KLF2, RASIP1, VEGFC and CDH3) were
selected for qRT-PCR veriﬁcation based on the frequency
of alternative splicing and interest level from a review of
the literature. Expression of two exons from diﬀerentially
expressed portions of each gene was quantiﬁed using qRT-
PCR on the same samples used in the array experiments
(Supplementary Figures). Array data was considered
veriﬁed if qRT-PCR demonstrated the same, directional
diﬀerence in expression between the diﬀerent regions of
the gene, or if novel alternative transcripts were speciﬁ-
cally identiﬁed based on PCR product size. For 4 of the
11 genes (CEACAM1, ERG, RASIP1 and VEGFC), the
qPCR data was in clear agreement with the array data.
One gene (CDKN2A) demonstrated diﬀerential expression
that was statistically borderline (Supplementary Figures).
In addition, while CDH3 exon-speciﬁc qPCR did not
appear to validate diﬀerential expression, a novel alterna-
tive transcript was identiﬁed that matched the array data
(described in detail below). Thus, 6 of the 11 selected genes
were considered validated while the remaining ﬁve genes
(ARMET, CDKN1A, FOXP1, KLF2 and CDKN2B) were
not veriﬁable by PCR. In three of ﬁve cases, we noted that
the exon array probes that did not show diﬀerential
expression were located in very G-C rich regions, raising
the possibility of cross hybridization as the reason for
erroneous exon array data. Of the six validated genes,
four (ERG, CDH3, CDKN2A, and CEACAM1) were
explored in more detail.
Differential expression of ERG splicevariants inlung
adenocarcinoma
Exon array analysis of ERG demonstrated diﬀerential
expression of splice variants in 20 of 20 tumor/normal
tissue pairs. Furthermore, the expression pattern observed
was consistent with diﬀerential expression of the two
known transcripts of ERG curated in the RefSeq database
(Figure 1a and b). Variant 1 (NM_182918.2) encodes a
short form with a unique 50 ﬁrst exon and an additional
exon towards the 30 end while variant 2 (NM_004449.3)
encodes a long form with three unique exons on the 50 end.
In order to validate the array data, we ﬁrst designed two
sets of qRT-PCR primers to quantify the diﬀerential
expression of unique versus shared exons. The results
demonstrate that the qRT-PCR data correlated with the
array data in the same individuals (Supplementary
Figures). Secondly, to prove that two transcripts exist in
this set of lung tumor and matched normal samples, we
designed a common primer set that spanned exon 7-8 of
variant 2 of ERG and exon 5-6-7 of variant 1. These data
demonstrate the existence of both ERG variants
(Figure 1c) in both tumor and normal tissue. Two addi-
tional transcript variants, identiﬁed in the UCSC genome
browser (uc002ywz.1 and uc002yxc.1), were also evaluated
but no expression was found in either tumor or normal
tissues. Finally, to speciﬁcally demonstrate diﬀerential
expression of variants 1 and 2 we designed primer sets
unique to the two transcripts and quantiﬁed expression
of each. This was performed in 35 tumor/normal pairs
(which included the 20 pairs used in the original array
analysis) (Figure 1c). We observed that ERG variant 2
was signiﬁcantly overexpressed (mean tumor/normal
ratio 4.73; paired t-test P-value¼0.0005) in tumor
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was slightly under-expressed in tumor samples compared
to normal (ratio¼0.74; P¼0.0186).
Identification of anovel CDH3 transcript variantin lung
adenocarcinoma
CDH3 is encoded by 16 exons and has only one known
transcript in the RefSeq database. Exon array data sug-
gested alternative splicing of exon 2 since all other exons
were expressed considerably higher in tumor than in
normal tissues. Interestingly, this was observed only in
female patients (8 of 14 cases) and not in any of six
male patients (Supplementary Figures). Given the estab-
lished gender diﬀerences in lung adenocarcinoma inci-
dence and survival (37), this ﬁnding was evaluated
further. QRT-PCR, with primers in exon 2 and in
exon 3, veriﬁed that exon 3 was expressed at much
higher levels (mean 24-fold tumor/normal) in tumor com-
pared with normal in these eight patients while exon 2 was
expressed only 3-fold higher in tumor versus normal.
However, exon 2 and exon 3 were expressed similarly
Table 1. Alternative spliced genes between tumor and normal in high frequency from Exon Array analysis
Symbol Entrez ID Gene name Frequency (%)
Genes with known splice variants where relevance of splice variants has been identiﬁed in cancer
ADAM12 8038 ADAM metallopeptidase domain 12 (meltrin alpha) 70
BCL6 604 B-cell CLL/lymphoma 6 (zinc ﬁnger protein 51) 55
CDKN2A 1029 Cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) 65
CEACAM1 634 Carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein) 70
DSCR1 1827 Down syndrome critical region gene 1 85
FGFR4 2264 Fibroblast growth factor receptor 4 90
Genes with known variants but where relevance of splice variants to cancer has not been identiﬁed
ADRA1A 148 Adrenergic, alpha-1A-, receptor 90
AKAP12 9590 A kinase (PRKA) anchor protein (gravin) 12 90
CCNE1 898 Cyclin E1 75
CDCA1 83540 Cell division cycle associated 1 90
DKK3 27122 Dickkopf homolog 3 (Xenopus laevis) 75
ERG 2078 v-ets erythroblastosis virus E26 oncogene like (avian) 100
FEZ1 9638 Fasciculation and elongation protein zeta 1 (zygin I) 90
FPRL1 2358 Formyl peptide receptor-like 1 70
GSN 2934 Gelsolin (amyloidosis, Finnish type) 75
KL 9365 Klotho 80
RASGRF1 5923 Ras protein-speciﬁc guanine nucleotide-releasing factor 1 95
TBX3 6926 T-box 3 (ulnar mammary syndrome) 50
TNFSF11 8600 Tumor necrosis factor (ligand) superfamily, member 11 55
ZBTB16 7704 Zinc ﬁnger and BTB domain containing 16 80
Genes with novel splice variants
ANKRD1 27063 Ankyrin repeat domain 1 (cardiac muscle) 75
APCDD1 147495 Adenomatosis polyposis coli down-regulated 1 65
ARHGEF3 50650 Rho guanine nucleotide exchange factor (GEF) 3 85
ARMET 7873 Arginine-rich, mutated in early stage tumors 85
CDH1 999 Cadherin 1, type 1, E-cadherin (epithelial) 60
CDH3 1001 Cadherin 3, type 1, P-cadherin (placental) 40
CXCL5 6374 Chemokine (C-X-C motif) ligand 5 60
EMP2 2013 Epithelial membrane protein 2 65
FSTL3 10272 Follistatin-like 3 (secreted glycoprotein) 70
GATA2 2624 GATA binding protein 2 95
GATA6 2627 GATA binding protein 6 90
HCK 3055 Hemopoietic cell kinase 80
IGFBP6 3489 Insulin-like growth factor binding protein 6 75
ITGA5 3678 Integrin, alpha 5 (ﬁbronectin receptor, alpha polypeptide) 55
KLF2 10365 Kruppel-like factor 2 (lung) 85
NFIL3 4783 Nuclear factor, interleukin 3 regulated 90
PGR 5241 Progesterone receptor 70
PIAS1 8554 Protein inhibitor of activated STAT, 1 60
PTHR1 5745 Parathyroid hormone receptor 1 100
RAMP2 10266 Receptor (calcitonin) activity modifying protein 2 100
RASIP1 54922 Ras interacting protein 1 100
SMAD6 4091 SMAD, mothers against DPP homolog 6 (Drosophila) 90
SPARC 6678 Secreted protein, acidic, cysteine-rich (osteonectin) 80
SRPX 8406 Sushi-repeat-containing protein, X-linked 100
SSBP2 23635 Single-stranded DNA binding protein 2 80
TBX2 6909 T-box 2 95
TGFBR3 7049 Transforming growth factor, beta receptor III (betaglycan, 300kDa) 55
VEGFC 7424 Vascular endothelial growth factor C 85
Known or Novel splice variants were based on Entrez Gene database and relevance to cancer was based on PubMed search. Both performed on
31 December 2007.
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other six female patients and in all male patients, thus
validating the array data. Next, in order to further char-
acterize the area of exon 1-3, we designed a forward
primer in exon 1 and reverse primer across the junction
of exons 3 and 4. RT-PCR products, visualized on a gel,
showed the expected 283bp band for the normal trans-
cript and a shorter (168bp) band (Figure 2a).
Sequencing of these two bands (Figure 2b) conﬁrmed
the the presence of the normal transcript (283bp band)
Tissue Type
Patient ID
201 bp, variant 1
129 bp, variant 2
(c)
(d) ERG V1 (mean T/N ratio=0.74, P=0.0186) ERG V2 (mean T/N ratio=4.73, P=0.0005)
Common R Primer / 
V1 R Primer
 
V1 F primer
Common F Primer
V2 R Primer
V2 F Primer
1
2
3
4
5
Variant 1
Variant 2
1 2
4
3
5
(a)
3′ 5′
T/N ratio V1 vs V2 (P=1.8478e-15)
(b)
236 260 416 419 432 459 519 522
TNTNTNTNTNTNTNTN
tumor normal tumor normal ERG V1 ERG V2
Figure 1. Exon array analysis and PCR analysis for alternative transcript variants of ERG.( a) Exon structure for ERG variant 1 (NM_182918.2)
and variant 2 (NM_004449.3) showing the location of PCR primers used for expression analyses. (b) Partek GS alternative splice analysis of exon
expression data in 20 patients. The graph shows mean expression value and standard error for each probe set in tumour (blue) and normal (normal)
groups. (c) veriﬁcation of PCR product size diﬀerence for two variants using primers 1 and 3. (d) Quantiﬁcation of the two variants using primer set
1 and 2 for variant 1 and primers 4 and 5 for variant 2 in tumour/normal paired samples (tissue pairs are joined by solid lines) from 35 patients.
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exon 2 (168bp). To evaluate expression of this novel
alterative transcript (referred to as CDH3 E2 skipping
transcript, or variant transcript, from this point forward),
qRT-PCR was performed with primers unique to each
CDH3 transcript. This was performed in paired tumor/
normal tissue from 35 patients and the results are shown
in Figure 2. Based on a threshold of 40 cycles, four
patients were negative for the E2 skipping transcript in
both tumor and normal tissue, one patient was negative
in tumor and positive in normal, 19 patients showed
expression in tumor but not in normal, and 11 patients
showed expression in both tissue types (Figure 2c). In all
11 patients, expression of the E2 skipping transcript was
higher in tumor than in normal tissues. Therefore the E2
skipping transcript was overexpressed in 86% (30 of 35) of
tumors (Figure 2d). However in this expanded patient
cohort there was no statistically signiﬁcant gender diﬀer-
ence in the frequency or expression level of the E2 skip-
ping transcript when compared with gender. Finally, the
normal CDH3 transcript was also found to be signiﬁcantly
overexpressed in tumor compared with normal
(Figure 2d).
Identification ofCDKN2A transcript variant2in lung
adenocarcinoma
RefSeq databases indicate several transcript CDKN2A
variants which diﬀer in their ﬁrst exons. At least three
alternatively spliced variants, each encoding distinct pro-
teins have been reported with variants 1, 3, and 4 encoding
P16, Isoform 3, and ARF respectively (Figure 3a). The
data from the exon arrays (Figure 3b) and qRT-PCR
veriﬁcation (Supplementary Figures) suggested the pre-
sence of a further splice variant of this gene. Analysis of
the Aﬀymetrix probe design and NCBI GenBank data-
bases identifed a cloned sequence originating from testis
tissue (Accession #: BG717152, GenBank ID: 13996339)
and a mRNA sequence, CDKN2A transcript variant 2
(Accession #: NM_058196, GenBank ID: 17738295).
However, the record was temporarily removed by NCBI
staﬀ since the variant has not been conﬁrmed. Four
unique PCR primer sets were designed to assess all four
possible transcript variants in this set of lung tumor/
normal tissue. Variant 3 was not expressed in lung tissues
but the three other variants were all expressed (Figure 3c).
Variant 2 was also expressed in lung cancer cell lines
Tissue Type
Patient ID
Gender
283 bp, normal transcript
168 bp, novel transcript
(a)
283 bp 168 bp
(b)
(d)
Exon 2 skipping 
variant  # of patients Frequency 
(%)
Tumor Normal Male Female Total
−− 2 2 4 11.4
+− 6 13 19 54.4
−+ 0 1 1 2.8
++ 6 5 11 31.4
Total 14 21 35 100.0
(c)
TNT
236
MFFMMFFF
260 416 419 432 459 519 522
NTNTNTNTNTNTN
Exon 1 Exon 3 Exon 1 Exon 2 Exon 3
CDH3 normal transcript 
mean T/N ratio=20.46, p=6.4786e-10)
CDH3 E2 skipping variant 
mean T/N ratio=42.86, p=1.9347e-10)
tumor normal tumor normal
....
Figure 2. Identiﬁcation, validation, and quantiﬁcation of novel CDH3 transcript variants. (a) Identiﬁcation of an alternative CDH3 transcript using
PCR primers located in exon 1 and across the exon 3-4 boundary. (b) DNA sequencing results for the two PCR products demonstrating skipping of
exon 2. (c) Frequency of the E2 skipping transcript expressed in 35 patients. (d) Speciﬁc quantiﬁcation of the two variants in tumour/normal paired
samples (tissue pairs are joined by solid lines) from 35 patients.
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D
B
1
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5
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9
H
1
2
9
9
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R
V1 (p16)
V4 (Arf)
V3 (Isoform3)
3′ 5′
V2 (Isoform2)
1 2 3
5
6
4 4
E1 E2 E3
(a)
V2 R Primer 
Common R Primer
V2 F primer
V1 F Primer
V3 F Primer
V4 F Primer
1
3
4
5
6
2
(b)
-190 bp
-148 bp
TNTNTNTNTNTN
Arf p16 Isoform3 (c)
tumor normal tumor normal tumor normal
(e)
(d)
... … ....
intron1-2 Exon 2 Exon 2 Exon 3
...
-377 bp
Isoform2
TNTNTNTNTNTNTNTNTNT
P16 (mean T/N ratio=1.75, P=0.1439) Arf (mean T/N ratio=103.01, P=0.0035) Isoform2 (mean T/N ratio=20.10, P=0.0186)
Figure 3. Exon array analysis and PCR analysis for alternative transcript variants of CDKN2A.( a) Exon structure for CDKN2A transcript variants 1
(NM_000077), 2 (NM_058196), 3 (NM_058197) and 4 (NM_058195) indicating the location of PCR primers used for expression analyses. (b) Partek
GS alternative splice analysis of exon expression data in 20 patients. The graph shows mean expression value and standard error for each probe set
in tumour (blue) and normal (normal) groups. (c) veriﬁcation of PCR product size diﬀerence for three variants using primers 1 and 3 (variant 2/
isoform2), 2 and 4 (variant 1/p16) and 2 and 6 (variant 4/Arf). Variant 3 was not detected using primers 2 and 5. (d) DNA sequencing results of
isoform 2. Sequencing shows intronic sequence upstream of exon 2 but also reads directly into exon 3 eliminating the possibility of genomic DNA as
the source of the PCR product. (e) Quantiﬁcation of variant P16 (using primers 2 and 4), Arf (2 and 6), and Isoform 2 (2 and 3) in tumour/normal
paired samples (tissue pairs are joined by solid lines) from 33 patients.
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which contains 10 combined cancer cell line RNAs, but
not in the lung cancer cell line A549. Furthermore, DNA
sequencing of the 377bp variant 2 PCR product con-
ﬁrmed that the transcript encodes a portion of intron 1,
consistent with the reported variant 2 mRNA (Figure 3d).
Finally, quantiﬁcation of three variants in 33 paired
tumor and normal tissues showed that variant 1 (p16)
was not expressed signiﬁcantly diﬀerently between
tumor and normal (mean tumor/normal ratio¼1.75;
P¼0.1439). Both variant 2 (Isoform 2, mean tumor/
normal ratio¼20.1; P¼0.0186) and variant 4 (ARF,
mean tumor/normal ratio¼103.01; P¼0.0035) were sig-
niﬁcantly overexpressed in tumor compared to normal
(Figure 3e).
Quantification of CEACAM1 transcript variants inNSCLC
CEACAM1 is encoded by nine exons with two known
variants in the RefSeq database. Variant 1 uses all nine
exons while variant 2 is missing exon 7 (Figure 4c).
Our array data demonstrated higher expression of
exons 1 through 6 as well as 8 and 9 in tumors versus
normal while expression of exon 7 was essentially equal
(Supplementary Figures). This was observed in 14 of 20
(70%) tissue pairs and suggested diﬀerential expression of
the two known CEACAM1 variants in lung tumor and
normal tissues as reported previously (38). Furthermore,
the exon array data was veriﬁed by qRT-PCR using PCR
primer sets designed to amplify exon 7 and exon 8 speci-
ﬁcally in the same samples (Supplementary Figures).
Expression of CEACAM1 was reduced in malignant
tissues as compared with corresponding normal tissues
deriving from breast (39), prostate (40), colon (41),
and endometrium (42). These ﬁndings indicated that
CEACAM1 might suppress carcinogenesis. However, in
contrast, high expression of CEACAM1 protein was
seen in lung tumor tissues and also correlated with poor
survival in lung cancer (43–45). Since these studies did not
examine expression of the two CEACAM1 variants
CEACAM1 V1
Mean T/N  ratio=3.53
P=0.0014
(a) CEACAM1 V2
Mean T/N ratio=36.42
P=0.000002
Paired tumor/normal ratio (V1 vs V2)
P=6.0221e-10
CEACAM1 V1 (b) CEACAM1 V2 (c)
CEACAM1 V1
CEACAM1 V2 
1 2
3′ 5′
3 4 V1  R Primer
V1 F primer
V2  R Primer
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Figure 4. Quantiﬁcation of CEACAM1 variants in NSCLC, colon and breast cancer patients. (a) Expression of CEACAM1 variant 1 and variant 2
in 35 tumour/normal paired samples from lung adenocarcinoma patients (tissue pairs are joined by solid lines) and in 43 lung adenocarcinoma
(n¼11) and squamous cell carcinoma (n¼32) samples only (without matched normals). The third graph shows the tumour/normal expression ratio
for variant 1 and 2 in the 35 matched tissue pairs. (b) Expression of variant 1 and variant 2 in non-paired tumour and normal samples from colon
and breast cancer patients (10 patients each). (c) Exon location and PCR primers locations for qPCR of variant 1 (NM_001712; primers 1 and 2),
variant 2 (NM_001024912; primers 3 and 4).
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variants 1 and 2 of CEACAM1 and analyzed expression
of each in lung, breast and colon tumors plus normal
tissues from each organ site. In 35 lung adenocarcinoma
patients we found that CEACAM1 variant 2 was highly
and signiﬁcantly overexpressed in paired tumor versus
normal (tumor/normal ratio¼36.42; P¼0.000002) while
variant 1 was only slightly overexpressed in tumor (tumor/
normal ratio¼3.53; P¼0.0014). Furthermore, analysis of
an additional 43 lung tumors, including squamous cell
cancers, revealed expression levels indistinguishable from
the original 35 adenocarcinoma samples (Figure 4a).
In the breast and colon tissues however, we found no
signiﬁcant diﬀerences in expression of either variant 1 or
variant 2 in tumor versus normal (unmatched) samples
(Figure 4b). Given this data we postulated that overex-
pression of CEACAM1 variant 2 in lung cancer may be
responsible for the survival diﬀerences observed between
tumor types. However, an analysis of disease-free survival
in our cohort of 78 lung cancer patients including
48 stage I and 30 higher stages (median follow up
24 months) showed no association of CEACAM1 variant
1 or 2 expression with patient survival (Cox regression
P-values 0.715 and 0.536, respectively).
DISCUSSION
In this study we have performed an extensive identiﬁcation
and veriﬁcation of alternative splice variant gene expres-
sion in NSCLC. To our knowledge, this study is the ﬁrst
such genome wide analysis of alternative splicing events
in NSCLC or any other tumor type. Our results indicate
that approximately 13% of the 17800 core RefSeq genes
appear to have alternative transcripts that are diﬀeren-
tially expressed between lung adenocarcinoma and
adjacent normal lung tissue. Furthermore, the largest
subsets of these alternatively spliced genes appear to be
cancer related and/or involved in cellular processes such
as growth and proliferation. For some genes, alterna-
tive transcripts have already been identiﬁed but we now
demonstrate their diﬀerential expression in cancer.
In many cases however, our microarray data indicates
the presence of diﬀerentially expressed alternative tran-
scripts that are currently unidentiﬁed. Thus it appears
that diﬀerential expression of alternative transcripts is
frequent in NSCLC and that this may be a valuable
resource for the development of novel diagnostic, prog-
nostic and therapeutic tools.
While the ability to analyze alternative transcript
expression on a genome wide scale is very powerful,
veriﬁcation and validation of this data is labor intensive.
For this reason, we chose to focus on genes that have
previously been associated with cancer, and where diﬀer-
ential expression occurred in >50% of tumor/normal
tissue pairs. In total, 11 genes were examined and we
were able to validate the array data for six of them.
Thus, veriﬁcation and validation of data from the exon
arrays is clearly required. Alternative transcript expression
for four of these genes was studied in more detail.
The ERG (V-ETS avian erythroblastosis virus E26
oncogene homolog) protein shares signiﬁcant homology
with both 50and 30 regions of the viral ETS1 oncogene,
ETS1, suggesting that it belongs to the ETS oncogene
family. ERG is located at chromosome band 21q22 and
has been identiﬁed as the target of genomic rearrangement
events in acute myeloid leukemia (46), Ewing’s sarcoma
(47) and prostate cancer (48–50). In acute myeloid
leukemia (AML) and Ewing’s sarcoma ERG has been
associated with several translocation fusion partners
including ELF4, FUS1 and EWSR1 (46,51,52). Further-
more, high expression of ERG in the absence of karyo-
typic rearrangement or ampliﬁcation was demonstrated
to be an adverse prognostic factor in patients with AML
(53). In prostate cancer, ERG is frequently fused to a
nearby gene, TMPRSS2 resulting in androgen regulation
of ERG and several reports now indicate that the presence
of this fusion is a poor prognostic indicator in prostate
cancer (54,55). Interestingly, none of the reports cited
above discuss the existence of two ERG variants and
how these are related to the fusion product. Our analysis
of variant-speciﬁc expression clearly showed that variant 2
has much higher expression in tumor compared to the
paired normal lung tissue while variant 1 has similar or
lower expression in tumors. Thus it seems that the onco-
genic eﬀect of ERG may be exerted through functions
encoded by variant 2 and expression of fusion gene pro-
ducts should also be closely evaluated for which ERG
variant is present.Further investigations are required
to identify the functional diﬀerences between the two
variants and could lead to more targeted drug discovery.
The cadherins are a family of transmembrane proteins
that mediate calcium-dependent cell-cell adhesion at adhe-
rens junctions. The cytoplasmic domain of cadherins
binds to A and G catenins and is linked to the actin
cytoskeleton via A catenin (56). These interactions are
vital for stable cell-cell interactions and maintenance of
normal cell physiology. In cancer, disruption of the
adherens junctions, for example by downregulation
or inactivating mutation of cadherins, can result in
epithelial-to-mesenchymal transition, increased prolifera-
tion, invasion and metastasis (56,57). In part, this may be
mediated by the release and accumulation of B catenin
which, when translocated to the nucleus induces transcrip-
tion of genes such as cyclin D1 and c-myc.
While the role of the prototypic cadherin, E-cadherin
(CDH1) as a classic tumor suppressor gene in cancer is
well established the role of P-cadherin remains unclear as
it behaves diﬀerently depending on the tumor type being
studied. For example, in melanoma, the loss of P-cadherin
(and E-Cadherin) allows invasion and migration of
cells and thus P-cadherin appears to be acting as a pro-
adhesion tumor suppressor (58,59). In breast cancer
however, high expression of P-cadherin strongly corre-
lated with high histologic grade, increased proliferation
and poor patient survival (60,61). Furthermore, in pan-
creatic cancer cell lines, overexpression of P-cadherin
resulted in increased cell motility, cytoplasmic accumula-
tion of catenins and activation of the Rho GTPases,
Rac1 and Cdc42 (62).
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lung tumors compared to normal lung but also identiﬁed
overexpression of an alternative splice variant in which
exon 2 is missing. Analysis of the resulting mRNA indi-
cates that the normal ATG initiation codon is placed out
of frame and would result in a truncated protein after only
27 amino acids. This would clearly result in an inactive
protein and would ﬁt with a tumor suppressor function for
P-cadherin in lung cancer if it were not for the fact that
full length P-cadherin mRNA is actually overexpressed in
our tumors. However, upon further analysis we identiﬁed
several alternative in frame ATG codons downstream
of the known translation start site. Furthermore, at least
two of these putative alternative start sites have kozak
sequences that are believed to be active in other genes.
Protein translation initiated at either of these sites would
result in a P-cadherin protein lacking the signal peptide
and most of the extracellular domain, while retaining the
transmembrane domain, juxtamembrane domain and the
catenin binding domain. If such a protein were to be over-
expressed in tumors one can easily envision disruption of
the adherens junctions in a dominant manner leading to
catenin accumulation and tumorigenesis.
Its is well known that multiple transcripts are
transcribed from the CDKN2A (cyclin-dependent kinase
inhibitor 2A) locus. CDKN2A is an extensively studied
tumor suppressor locus that is frequently mutated or
deleted in a wide variety of tumor types. Exploration of
the RefSeq database identiﬁed four transcript variants
potentially transcribed from this locus of which three are
considered veriﬁed. Variant 1 gives rise to the p16 protein
and variant 4 gives rise to the alternative reading frame
p14/ARF protein. Variant 4 also gives rise to a shorter
protein product (p19smARF) which results from an alter-
native translation start site (63). Variant 3 gives rise to
a longer protein that shares the same reading frame as
p16 and appears to be speciﬁcally expressed in the
pancreas. In addition, another transcript variant (p16g)
was recently identiﬁed (64) but has yet to be curated in
the RefSeq databases. Finally, variant 2 lacks exons 1a
and 1b, and exon 2 is slightly longer due to inclusion of
an additional 100 bases of intronic sequence. Variant 2
may also have a shorter 30 UTR than p16 or Arf.
Variant 2 was originally cloned from testis tissue but has
been temporarily removed by RefSeq staﬀ for further
evaluation.
In cancer, inactivation of the p16INK4a/ARF tumor
suppressor genes is frequently mediated through genomic
deletion, promoter methylation or inactivating mutation
leading to loss of p53 and Rb dependent cell cycle regula-
tion (65). In NSCLC, loss of heterozygosity and/or homo-
zygous deletion of the CDKN2A locus on chromosome
9p21 has been reported at frequencies up to 40% (8).
In our study,  30% of tumors demonstrated reduced
expression of all three measured transcripts (p16, ARF
and variant 2) and this is likely a result of genomic
deletions. However, in the remaining tumors expression
of ARF and variant 2 (but not p16) were signiﬁcantly
higher than in paired normal tissue. Overexpression
of ARF in cancer has now been reported several times
(66–68) and has been associated with poor diﬀerentiation
status in hepatocellular carcinoma (67) and worse out-
come in B-cell lymphomas (66). Similarly, overexpression
of p16 has also been observed and has been associated
with progression and poor survival in ovarian cancer
(69), prostate cancer (70) and breast cancer (71). While
overexpression of p16 and ARF appears to contradict
their known cellular functions as tumor suppressors,
mechanisms have been proposed whereby this event may
be explained through activating mutations in Rb or induc-
tion of myc and ras (68,72,73). However, our data suggests
an alternative: that the variant 2 transcript may account
for the previously observed overexpression. Variant 2 was
originally believed to give rise to a new isoform (Isoform
2) of P16 with the ﬁrst amino acid encoded by an in frame
ATG that is present in the original exon 2. However, we
also identiﬁed an alternative ATG codon that is in the
extended exon 2 and is in frame with ARF. This alterna-
tive ATG has a reasonably good Kozak sequence
(CCGTCATGC) and, being upstream of the putative
p16 isoform 2 start site, would presumably dominate
translation initiation. This putative ARF isoform would
lack the amino terminal portion of ARF and would there-
fore be unable to bind TBP-1, E2F, Myc, FoxM1, CTBP1
or mdm2 (74) and may be unable to block cell cycle
progression. However others have shown that the carboxy
terminus of artiﬁcially truncated ARF still accumulates
in the nucleolus (75–77) and thus this putative ARF iso-
form could theoretically act as a dominant negative, thus
explaining how overexpression of ARF may be pro-
tumorigenic.
CEACAM1 [carcinoembryonic antigen-related cell
adhesion molecule 1 (biliary glycoprotein)] is a cell–cell
adhesion molecule that also plays a role in signal transduc-
tion. Two common variants are known for CEACAM1;
one with a long cytoplasmic domain (L form or variant 1)
and one with a short cytoplasmic domain (S form or
variant 2). The expression of CEACAM1 in cancer has
been extensively studied but early reports appeared to be
contradictory. For example, reduced expression of
CEACAM1 was reported in breast, colon, prostate and
endometrial cancer (39,41,78) and CEACAM1 was there-
fore considered to be a negative regulator of tumor cell
growth. However, in melanoma (79) and lung cancer
(43,44), several reports indicated that CEACAM1 was
overexpressed in tumors and that this was associated
with disease progression and poor outcome. In 1997
Turbide et al. (80) found that the L form of CEACAM1
exhibited a tumor suppressive phenotype and that this was
dominant over expression of the S form. Furthermore,
using semi-quantitative RT-PCR Wang et al. (38) found
that the L form of CEACAM1 predominated in normal
lung while the S form appeared more abundant in tumors.
Thus they proposed that isoform switching rather than
CEACAM1 downregulation occurs in NSCLC as opposed
to other tumor types. Our quantitative analysis clearly
demonstrates a switch in abundance from the L form
(variant 1) to the S form (variant 2) in NSCLC and we
also demonstrate that no such switch appears to occur in
breast cancer or colon cancer. Furthermore, we also ana-
lyzed a publicly available GeneChip Human Exon 1.0 ST
array data set from colon (33) and found no signiﬁcant
6544 Nucleic Acids Research, 2008, Vol. 36, No. 20diﬀerential expression of CEACAM1 variants in
those 10 pairs of colon tumor/normal samples (data not
shown). Thus our ﬁndings support the hypothesis that the
tumor suppressive or oncogenic eﬀects of CEACAM1 are
splice variant dependent and that expression of the two
variants is diﬀerentially regulated in diﬀerent tissue types.
In conclusion, our data demonstrates that diﬀerential
expression of alternative splice variants is a common
event in NSCLC. It also shows that in addition to identi-
ﬁcation of novel, cancer-related splice variants, additional
information can be gained even with regard to extensively
studied, cancer-related genes. Splice variant expression
should be considered in future genome-wide expression
studies and may lead to novel diagnostic, prognostic or
therapeutic strategies in the ﬁght against cancer.
(GeneChip Human Exon 1.0 ST array cell ﬁles along
with GC-RMA data from core gene probsets and patient
information have been submitted to GEO databases and
GEO Accession # is GSE12236).
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